from the speedily evolving field of oncology research, correct and economical mutation screening is essential for developing targeted therapies. The KRAS solutions System performs a pivotal role in this landscape by providing complete options for KRAS mutation profiling and Evaluation. KRAS mutations, found in around 95% of RAS-connected oncogenic